Mylan, Allergan launch fight over Restasis eye drop patents

Allergan (NYSE:AGN) said this week that it will “vigorously defend” the patents for its Restasis eye drops, after the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board agreed to an inter partes review of 6 patents as requested by generic competitor Mylan (NSDQ:MYL). The patents are valid until August 2024. “Allergan is disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that protect Restasis,” the company wrote in a statement yesterday. “Allergan is currently reviewing the grounds for the decision to institute, and will continue to vigorously defend the patents in the IPR proceeding and pursue all legal options available to protect its products and intellectual property rights for this product.” Get the full story at our sister site, Drug Delivery Business News. The post Mylan, Allergan launch fight over Restasis eye drop patents appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news

Related Links:

Authors: Yousefi A, Nasehi S, Arshi S, Nabavi M, Bemanian MH, Shokri S, Seif F, Khoshmirsafa M, Saeedi Y, Rajabian B, Mahjoub F, Sadeghian M, Talachian E, Fallahpour M PMID: 32496031 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Authors: Skander D, Allenova A, Maurer M, Kolkhir P PMID: 32496030 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Publication date: Available online 4 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Roberto Padoan, Fulvia Chieco Bianchi, Maria Rita Marchi, Diego Cazzador, Mara Felicetti, Enzo Emanuelli, Andrea Vianello, Piero Nicolai, Andrea Doria, Franco Schiavon
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Despite important implications in the management of MS, clinicians often have little training or knowledge of the wide variations of cannabis.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
An acid-hydrolyzed wheat protein activates the inflammatory and NF-κB pathways leading to long TSLP transcription in human keratinocytes. J Toxicol Sci. 2020;45(6):327-337 Authors: Kuroda Y, Yuki T, Takahashi Y, Sakaguchi H, Matsunaga K, Itagaki H Abstract Hydrolyzed wheat proteins (HWPs) contained in cosmetics have occasionally caused immediate-type hypersensitivity following repeated skin exposure. Although the Cosmetic Ingredient Review Expert Panel concluded that
Source: Journal of Toxicological Sciences - Category: Toxicology Tags: J Toxicol Sci Source Type: research
George Lundberg discusses why the cause of death matters.Medscape Internal Medicine
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases Commentary Source Type: news
Allergists and immunologists dove into telemedicine'overnight'when the COVID crisis started, and they like it, but regulations will need to change before its use becomes permanent.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Read clinically focused news coverage of key developments from EAACI 2020Medscape Allergy &Immunology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Conference Coverage Source Type: news
Dr David Johnson on important new recommendations for managing and treating this once poorly researched disease.Medscape Gastroenterology
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology Commentary Source Type: news
Conditions:   Keratoconus;   Dry Eye;   Allergy Intervention:   Drug: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use Sponsor:   Illinois College of Optometry Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Legislation | Opthalmology | Restasis